In this study, we evaluate the use of clinically relevant non-ablative doses of radiation to guide and enhance the delivery of intravenously administered AMONs to brain tumor sites to silence MGMT and enhance the efficacy of CRT in orthotopic rat models of MGMT-positive human brain tumors. The gene discussed is MGMT; the disease is brain neoplasm.